Corneal Crollagen Crosslinking Outcomes In Patients With Pseudophakic Bullous Keratopathy

Published 2024 - 42nd Congress of the ESCRS

Reference: PP23.17 | Type: Free paper | DOI: 10.82333/jf5c-4r37

Authors: Oumayma Elmansouri* ¹ , Zineb Algouti ¹ , Housseine Aitlhaj ¹ , Mohamed Kriet ¹ , Fouad Elasri ¹

¹Ophthalmology department,Avicenna Military hospital,Marrakech,Morocco

Purpose

To evaluate the effectiveness and security of treatment with corneal collagen crosslinking in patients with pseudophakic bullous keratopathy .

Setting

We conducted a prospective study from September 2022 to September 2023 in the military hospital of Marrakesh including patients who underwent corneal collagen crosslinking pseudophakic for bullous Keratopathy.

Methods

A total of 18 eyes of 18 patients were included in the study. Corneal collagen cross linking using topical isotonic riboflavin followed by UVA radiations (3mW/cm² for 10 minutes) was performed in all the patients. Visual acuity (VA), visual symptoms and central corneal thickness (CCT) were recorded after 1, 3, and 6 months of CXL.

Results

Age of the patients ranged from 55 to 75 years with mean age 65.83 + 3.89 years. The mean pain score decreased from 8.1 before surgery to 3.1 ± 0.7 on day 7 (P = 0.001). The mean CCT decreased from a preoperative value of 724.8 ± 78.4 to 694.9 ± 77.9 μm by the end of the first month (P = 0.0001). The CCT remained stable at later follow-up. The BCVA improved from logarithm of the minimum angle of resolution (log MAR) 2.0 ± 0.5 preoperatively to log MAR 1.8 ± 0.5 by the end of the first month (P = 0.001). The subsequent follow-up showed a progressive deterioration in the BCVA to the preoperative levels at 6 months. Corneal bullae recurred in 8 patients at 6 months after an initial disappearance.

Conclusions

Corneal collagen cross linking is a temporary but effective symptomatic treatment of pseudophakic bullous keratopathy.